1. Home
  2. NEO

as of 12-23-2025 9:50am EST

$12.54
+$0.08
+0.64%
Stocks Health Care Precision Instruments Nasdaq

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Chart Type:
Time Range:
Founded: 2001 Country:
United States
United States
Employees: N/A City: FORT MYERS
Market Cap: 1.2B IPO Year: 1999
Target Price: $11.38 AVG Volume (30 days): 1.7M
Analyst Decision: Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.89 EPS Growth: N/A
52 Week Low/High: $4.72 - $19.11 Next Earning Date: 10-28-2025
Revenue: $709,162,000 Revenue Growth: 10.10%
Revenue Growth (this year): 10.9% Revenue Growth (next year): 9.88%

Stock Insider Trading Activity of NeoGenomics Inc. (NEO)

Olivo Alicia C

EVP, GC & Business Development

Sell
NEO Oct 16, 2025

Avg Cost/Share

$10.00

Shares

4,918

Total Value

$49,180.00

Owned After

43,022

SEC Form 4

Latest NeoGenomics Inc. News

NEO Breaking Stock News: Dive into NEO Ticker-Specific Updates for Smart Investing

All NEO News

Share on Social Networks: